Regorafenib is an orally available multikinase inhibitor, whose main targets are kinases involved in angiogenesis (VEGFR1–3 and TIE2), oncogenesis (KIT, RET, RAF1, and BRAF), tumor microenvironment (PDGFR and FGFR), and tumor immunity (colony stimulating factor 1 receptor)2,3. This evidence concerns the gene BRAF and neoplasm.